Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
0.189
+0.007 (3.90%)
At close: Nov 22, 2024, 4:00 PM
0.186
-0.003 (-1.53%)
After-hours: Nov 22, 2024, 4:11 PM EST

Lyra Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Revenue
1.471.561.360.29--
Upgrade
Revenue Growth (YoY)
3.37%14.31%378.25%---
Upgrade
Cost of Revenue
49.6748.0338.829.6912.52-
Upgrade
Gross Profit
-48.2-46.47-37.43-29.41-12.52-
Upgrade
Selling, General & Admin
19.2519.0617.5614.219.694.49
Upgrade
Research & Development
-----12.03
Upgrade
Operating Expenses
19.2519.0617.5614.219.6916.52
Upgrade
Operating Income
-67.44-65.53-54.99-43.62-22.21-16.52
Upgrade
Interest & Investment Income
3.864.51.040.10.080.21
Upgrade
EBT Excluding Unusual Items
-63.59-61.03-53.95-43.51-22.13-16.31
Upgrade
Asset Writedown
-24.72-1.59-1.32---
Upgrade
Pretax Income
-97.56-62.62-55.27-43.51-22.13-16.31
Upgrade
Income Tax Expense
0.050.060.01---
Upgrade
Net Income
-97.61-62.68-55.28-43.51-22.13-16.31
Upgrade
Preferred Dividends & Other Adjustments
----0.120.31
Upgrade
Net Income to Common
-97.61-62.68-55.28-43.51-22.24-16.62
Upgrade
Shares Outstanding (Basic)
6450301390
Upgrade
Shares Outstanding (Diluted)
6450301390
Upgrade
Shares Change (YoY)
29.41%64.72%132.83%51.17%4150.62%21.66%
Upgrade
EPS (Basic)
-1.52-1.26-1.83-3.35-2.59-82.23
Upgrade
EPS (Diluted)
-1.52-1.26-1.83-3.35-2.59-82.23
Upgrade
Free Cash Flow
-80.9-64.35-43.55-29.21-22.92-13.97
Upgrade
Free Cash Flow Per Share
-1.26-1.29-1.44-2.25-2.67-69.10
Upgrade
Operating Margin
-4584.91%-4205.91%-4034.48%-15303.51%--
Upgrade
Profit Margin
-6635.76%-4023.11%-4055.61%-15267.72%--
Upgrade
Free Cash Flow Margin
-5499.66%-4130.36%-3195.08%-10247.37%--
Upgrade
EBITDA
-67.04-65.25-53.92-42.61-22.11-16.49
Upgrade
D&A For EBITDA
0.410.281.0710.10.03
Upgrade
EBIT
-67.44-65.53-54.99-43.62-22.21-16.52
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.